Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

Abstract : Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and MET Patients with metastatic EGFR-mutated NSCLC displaying high MET overexpression or MET Forty two patients were included. The median overall survival (OS), and the median post EGFR TKI progression overall survival (PPOS) were 36.2 months [95%CI 27.3-66.5] and 18.5 months [95%CI 10.6-27.4] respectively. Nineteen out of 36 tumors tested for MET FISH had MET MET-driven resistance to EGFR TKI defines a specific pattern of resistance characterized by low objective response rate to MET inhibitors given alone and overlapping with T790M mutations. Further studies are warranted to define adequate therapeutic strategies for MET-driven resistance to EGFR TKI.
Liste complète des métadonnées

Littérature citée [39 références]  Voir  Masquer  Télécharger

https://hal.univ-lille.fr/hal-02543375
Contributeur : Lilloa Université de Lille <>
Soumis le : mercredi 15 avril 2020 - 12:15:58
Dernière modification le : mardi 18 août 2020 - 17:04:03

Fichier

Outcome of EGFR-mutated.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Citation

Simon Baldacci, Julien Mazieres, Pascale Tomasini, Nicolas Girard, Florian Guisier, et al.. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget, Impact journals, 2017, 8 (62), pp.105103-105114. ⟨10.18632/oncotarget.21707⟩. ⟨hal-02543375⟩

Partager

Métriques

Consultations de la notice

166

Téléchargements de fichiers

153